0000891293-22-000033.txt : 20220617
0000891293-22-000033.hdr.sgml : 20220617
20220617165744
ACCESSION NUMBER: 0000891293-22-000033
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220617
FILED AS OF DATE: 20220617
DATE AS OF CHANGE: 20220617
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KIRSKE DAVID
CENTRAL INDEX KEY: 0001276750
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-28386
FILM NUMBER: 221024732
MAIL ADDRESS:
STREET 1: C/O CTI BIOPHARMA CORP.
STREET 2: 3101 WESTERN AVE., SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CTI BIOPHARMA CORP
CENTRAL INDEX KEY: 0000891293
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 911533912
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 800
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: 2062827100
MAIL ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 800
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER COMPANY:
FORMER CONFORMED NAME: CELL THERAPEUTICS INC
DATE OF NAME CHANGE: 19960321
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2022-06-17
0
0000891293
CTI BIOPHARMA CORP
CTIC
0001276750
KIRSKE DAVID
CTI BIOPHARMA CORP.
3101 WESTERN AVE., SUITE 800
SEATTLE
WA
98121
0
1
0
0
EVP, Chief Financial Officer
common stock
2022-06-17
4
M
0
10000
1
A
17397
D
common stock
2022-06-17
4
S
0
10000
6
D
7397
D
common stock
2022-06-17
4
M
0
50000
3.3
A
57397
D
common stock
2022-06-17
4
S
0
50000
6.2501
D
7397
D
Non-Qualified Stock Option (right to buy)
1
2022-06-17
4
M
0
10000
0
D
2030-03-11
Common Stock
10000
340000
D
Non-Qualified Stock Option (right to buy)
3.3
2022-06-17
4
M
0
50000
0
D
2031-03-10
Common Stock
50000
150000
D
This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person.
One sixth of the shares underlying the option vested on 9/11/2020 and semi-annually thereafter until all the underlying shares will be fully vested on 3/11/2023.
One sixth of the shares underlying the option vested on 9/10/2021 and semi-annually thereafter until all the underlying shares will be fully vested on 3/10/2024.
David Kirske
2022-06-17